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ABSTRACT

The prevalence of diabetes continues to rise, but patients’ ability to obtain and maintain glycemic
control remains a challenge. In 2017, complications from diabetes resulted in over $300 billion
expenditures in lost productivity and medical costs. The nation’s approach to addressing this
problem starts with acknowledging the benefits that continuous glucose monitoring (CGM) as an
adjunct intervention could change the trajectory of both diabetic care outcomes and the national
expenditures associated with poor glycemic control, which leads to the destruction of other cells
such as those found in the heart, eyes, and kidneys. Moreover, CGM use has been associated
with reductions in glycated hemoglobin A1c (HbA1c) levels. Lower HbA1c levels in diabetes
patients translate to better glycemic control. If diabetes patients can improve glycemic levels,
they could prevent the severe complications associated with poor glycemic control. This
integrative review involved a detailed search, review, and analysis of the literature to further
evaluate the relationship between CGM use and HbA1c levels, reliability of CGM data, and
patients’ acceptance of CGM use for glycemic management.
Keywords: diabetes, adult diabetics, diabetes self-monitoring blood sugar tools,
home-based continuous glucose monitoring, HbA1c,
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SECTION ONE: FORMULATING THE REVIEW QUESTION
Introduction
Chronic diseases are a common phenomenon responsible for various health crises
suffered by millions residing in the United States (U.S.). Chronic diseases are a known leading
cause of death and disability nationally. Additionally, they are a driving force behind the
country’s $3.8 trillion yearly healthcare-related costs, which account for 90% of the nation’s
healthcare expenditures (National Center for Chronic Disease Prevention and Health Promotion
[NCCDPHP], 2021). Among the list of chronic illnesses, diabetes mellitus (DM) is one of seven
problematic health challenges existing alone or as a comorbidity for many Americans. The most
recent statistics indicate that six in ten adults have a chronic disease, and four in ten suffer from
two or more chronic illnesses (NCCDPHP, 2021, p. 1).
Diabetes directly impacts over 34.2 million Americans and prediabetes, a condition that
predisposes a person to develop diabetes, dwells in the shadows of 88 million adults, roughly
10% of the adult population residing in the U.S. (Gill et al., 2018). Type 2 diabetes mellitus
(T2DM), a preventable disease, accounts for 90–95% of all diabetes patients, and in 2017,
complications from diabetes resulted in over $300 billion expenditures in lost productivity and
medical costs. Consequently, diabetes ranked number seven of the top 15 leading causes of death
nationally, increasing from 1999 death rates (Centers for Disease Control and Prevention [CDC]:
Centers for Disease Control and Prevention, 2019). While prevention is key to reducing such
costs, successfully managing symptoms that curtail disease progression is the next best
alternative. Further, successful disease self-management is more likely to occur if patients have
access to improved management tools that can provide improved accurate health data (Lameijer
et al., 2021).
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Defining Concepts and Variables
The interest for this integrative review (IR) stemmed from a desire to understand adult
diabetes patients’ use of continuous glucose monitoring (CGM) and its relationship to HbA1c
levels. Therefore, the population of interest comprises adults with diabetes and the intervention is
defined as the use of a CGM and its relationship to the outcome variable of HbA1c levels.
According to Toronto and Remington (2020), establishing this criterion is required. Patients with
chronic diabetes are generally separated into two main groups, type 1 DM (T1DM) and T2DM.
The type of diabetes diagnosed determines a patient’s treatment plan. According to the American
Association of Endocrinology (2021), T2DM represents 90–95% of all diagnosed diabetes
patients. It represents a group of individuals with a metabolic condition where they either cannot
produce enough insulin, lack the ability to effectively use the insulin produced by the cells in
their own bodies, or exhibit a combination of both deficiencies. This challenge causes blood
glucose (blood sugar, glycemia) levels to become elevated, which causes preventable damage to
other critical organs. Glycated hemoglobin A1c (HbA1c) is the gold standard metric used to
determine how well diabetes patients manage their diabetes. It is a measurement obtained
through a blood sample that measures the average sugar level circulating on the blood’s
hemoglobin protein over the preceding 3 months (CDC, 2019). To reduce the risk of
complications from diabetes, the desired HbA1c level is < 7% (National Institute of Diabetes and
Digestive and Kidney Diseases [NIDDK], 2021).
T1DM represents approximately 5% of all diagnosed diabetes patients and is the second
most common type of diabetes. T1DM falls under the category of an autoimmune medical
condition, which means that the person’s body makes antibodies against the cells that are
responsible for making insulin, eventually destroying the beta cells of the pancreatic islets of
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Langerhans. This destruction results in these patients having to self-administer insulin for the rest
of their lives (NIDDK, 2021).
A glucose meter or glucometer (GM) is a portable electronic device that allows users to
test blood glucose levels using a lancet finger stick. Each blood sample obtained requires the user
to retrieve a sample by administering a finger stick with a lancet. The glucometer measures the
blood glucose level at one moment in time. It does not inform the user whether the blood glucose
level decreases or increases; therefore, the device does not provide directional glucose levels.
The GM is the traditional self-monitoring blood glucose (SMBG) tool used by patients with
diabetes to self-monitor and manage their blood glucose levels. The glucometer is a key glucose
monitoring tool used by patients with diabetes.
The at-home CGM is a portable electronic blood glucose monitoring device that allows
users to retrieve blood glucose levels via a sensor affixed to the user’s skin and stays in place
10–14 days, depending on the device’s manufacture. It allows users to view their blood sugar
levels anytime at-a-glance. It is sometimes called a real-time continuous glucose meter (rtCGM)
(Gill et al., 2018). Commonly used among patients with T1DM, these devices utilize technology
that offers users blood glucose levels delivered without additional finger sticks and with results
available within 1 to 5 min of each other (Azhar et. al., 2020). In addition, some CGM devices
inform the user of blood glucose trend direction. The technology has recently improved, and
these devices are currently being marketed to patients with T2DM due to the enhanced blood
glucose control benefits available and experienced by device users.
To avoid micro and macrovascular complications associated with poorly controlled
diabetes, successful glycemic control is required. A general international consensus when using
CGMs has determined that a percent time-in-range (%TIR) equates glucose values of 70–180
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mg/dL (approx. 3.9–10.0 mmol/L), time-above range (TAR) > 180 mg/dL (> 10.0 mmol/L) and
> 250 mg/dL, and time-below range (TBR) < 70 mg/dL and < 54 mg/dL (< 3.0 mmol/L)
(Vigersky and McMahon, 2019). When diabetes patients spend more time in TIR, HbA1c levels
improve (Advani, 2019).
Rationale for Conducting the Review
Complications due to diabetes are known to cause serious health problems like heart
disease, kidney failure, and blindness (CDC: Centers for Disease Control and Prevention, 2019).
When diabetes has been diagnosed, successful control of blood glucose levels is key in
preventing further complications and disease progression. Traditional self-care management
regimens include daily episodic blood glucose monitoring using a traditional GM device, which
could include one–three daily finger sticks required to obtain blood glucose level measurements.
Patients and healthcare providers use these measurements to help determine the patient’s daily
progress. The use of CGM technology has been reported to impact HbA1c levels (Azhar et al.,
2020). Currently, CGMs are not routinely covered by health insurance benefits for all diabetes
patients. Patients with T1DM generally enjoy the use of CGMs as a covered insurance benefit,
but this health care service is not generally experienced by patients diagnosed with T2DM.
However, in 2017 T2DM accounted for more than 90–95% of all diabetes patients and
associated U.S. healthcare costs (CDC: Centers for Disease Control and Prevention, 2019).
During the same year, the Advanced Technologies and Treatments for Diabetes Congress
convened an international panel of expert researchers and physicians to define specific metrics
information used to assess CGM data (Martin et al., 2019). Therefore, the rationale for
conducting this IR was to search, review, critique, and analyze relevant data that adds insight to
the relationship between CGM use and HbA1c levels in diabetes patients.

HOME-BASED CONTINOUS GLUCOSED MONITORING

11

Problem Statement
The U.S. healthcare economic burden due to complications associated with diabetes
needs to improve. Successful disease management is required to achieve positive patient
outcomes when disease prevention has not prevailed. When blood sugar levels of diabetes
patients are not well controlled, other organs such as the heart, the kidneys, and the eyes are
negatively impacted, resulting in less-than-optimal patient outcomes and increased U.S.
expenditures (CDC: Centers for Disease Control and Prevention, 2019). Patient studies have
proven that optimal glycemic control aids in the reduction of morbidity from diabetes (Kieu et
al., 2021). Traditional SMBG efforts have fallen short with helping to reduce national cost
expenditures of healthcare-associated complications resulting from progressive diabetes, which
classifies as a chronic disease. HbA1c levels have continued to trend upward among this
population (CDC, 2019). As discussed earlier, traditional episodic glucose measuring devices
provide patients with blood glucose levels at a given time, but these devices do not provide trend
information. Since most CGM devices have built-in technology with the capacity to deliver
blood glucose directional trend data as often as every 5 mins, the use of CGMs could prove more
beneficial (Advani, 2019). Trend data provides information to patients that could yield a more
accurate treatment response when compared with a treatment plan that lacks this type of detailed
information. When diabetes patients use CGM devices, patients have been found to experience
better glycemic control with lowered mean blood glucose levels (Beck et al., 2017). The use of
CGMs has also been associated with lowered HbA1c levels, and when compared with episodic
GMs, CGMs has proven more favorable among patients (Kropff et al., 2017).
Purpose of this Scholarly Project: IR
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In general, the purpose of IR is to provide a comprehensive summary of past empirical or
theoretical literature of what is known about a particular subject area and to share the synthesis
of literature regarding a healthcare topic or phenomenon to the interested groups (Whittemore &
Knafl, 2005). The purpose of this IR was to search, collect, review, analyze, and synthesize
relevant literature published from 2016–2021 to determine if the use of CGM devices in home
setting is a reliable, cost-effective, and user-friendly alternative over traditional episodic
(SMBG) devices used among adult diabetes patients, in lowering HbA1c levels. Preliminary
literary research for this IR suggested favorable evidence that supports this inverse relationship.
If the lowering of HbA1c levels is consistently found with the use of CGMs, this could benefit
all diabetes patients, especially those with T2DM, by improving success with diabetes
management and support for optimal health (Azhar et al., 2020). Furthermore, clinical
information gleaned from IRs can potentially impact healthcare practice and policy (Whittemore
& Knafl, 2005).
Findings from this IR will be shared with clinicians in the primary care setting and any
other interested parties, such as insurance companies. This evidence-based information can be
used to assist clinicians with guiding patients on the use of diabetic self-management tools like
CGMs. The ability of the family practitioner to assist diabetes patients in lowering their HbA1c
levels could positively impact this population group, the overall health of the community where
they reside and aid in lowering national expenditures associated with care rendered to diabetes
patients, especially those with T2DM.
Clinical IR Question
Does the use of home-based CGM devices in adults with diabetes improve HbA1c
levels?
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Data Collection Process
The reviewer completed the required CITI training (Appendix E) according to Liberty
University policy. Although this IR did not involve the participation of human participants,
approval from Liberty University’s Institutional Review Board (IRB) was sought and obtained
(See Appendix F) (IRB approval letter). The IRB approval was followed by a well-defined
literature search strategy that included clearly defined parameters to conduct a literature search.
According to Whittemore and Knafl (2005), this was necessary to obtain enhance rigor and a
comprehensive collection of data that was challenged for relevancy to the clinical question. The
reviewer of this IR used computerized databases with more than two strategies or filters with
clearly defined eligibility criteria. The use of electronic databases was effective and efficient
(Whittemore and Knafl, 2005).
Formulation of Inclusion and Exclusion Criteria of the Literature
A clinical question must be clearly defined to establish a comprehensive literary research
method to initiate a literature review (Toronto and Remington, 2020). After a clinical question
has been formalized, inclusion and exclusion criteria must be identified to help guide the data
search. Inclusion criteria for this project were peer-reviewed studies and journal articles that
evaluated the relationship between home-based CGM use and HbA1c levels in adult diabetes
patients. Exclusion criteria were newspaper articles, dissertation/thesis, trade publication articles,
and journal studies that were narrowly focused, such as those that solely studied children or
pregnant women with diabetes.
The study selection search included consultation with the school librarian and use of
electronic databases to identify full text, peered reviewed articles written in the English language
that covered published years of 2016–2021 and targeted the subject area of CGM as an
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intervention to monitor blood glucose levels in patients with diabetes (Table 1). Research efforts
were further refined with the specificity of search terms and keywords: adults’ diabetes selfmanagement tools, home-based continuous glucose monitors, home-based continuous glucose
monitors and hemoglobin A1c levels, home-based CGM and costs, using six databases (Cochran
Database, MEDLINE, CINAHL, Plus, PubMed, ProQuest, and government websites). The
disciplines used in the initial search included nursing, medicine, education, and public health.
Literature Search Results
Initial results using general terms of diabetes management tools yielded 56,133 articles.
With narrowing the data criteria to include home-based CGMs, the database search yielded 111
articles. When the search criteria included both terms home-based CGM and HbA1c, the
database search yielded 100 articles. When the term cost was added to portable CGM, 112
journals were yielded, and when the terms home-based CGM and patients with T2DM were used,
162 journals were populated. With further examination, removal of duplicates, 103 articles
remained. Following inclusion and exclusion criteria (Table 1), 50 full-text articles were assessed
for eligibility which rendered a total of 26 journals that were collected using the article title,
abstract, purpose, findings, and conclusions to establish topic relevancy to the IR clinical
question. The 24 articles excluded from this IR contained studies that solely focused on children,
hospitalized patients, or the study did not include information regarding HbA1c levels. The
selected articles were reviewed and examined for participant clarity and rigor (See Appendix A)
(Melnyk and Fineout-Overholt, 2015) and literature categorized by theme (See Appendix B).
The 26 articles selected for this IR provided information relevant to the clinical question
(Toronto and Remington, 2020) of CGM use by adult diabetes patients and HbA1c level
reduction (Advani et al., 2019; Al Hayek et al., 2017; Azhar et al., 2020; Beck et al., 2017; Chan
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et al., 2018; Eleftheriadou et al., 2019; Gilbert et al., 2021; Kropff et al., 2017; Lameijer et al.,
2021; Martin et al., 2019; Rivera-Ávila et al., 2021; Schlüter et al., 2020; Valenzano et al.,
2021;) Other articles were chosen because they support CGM data reliability by demonstrating a
linear relationship between TIR and HbA1c or estimated HbA1c (eHbA1c) and asymptomatic
hypoglycemia (Al Hayek et al., 2017; Beck et al., 2019; Fabris et al., 2020; Gabby et al., Hirsch
and Verderese, 2017; Kropff et al., 2017; Martin et al., 2019; Mattishent & Loke, 2018;
Ushigome et al., 2020; Vigersky & McMahon, 2019; Xu et al., 2020; Yamada et al., 2020).
Patient acceptance or satisfaction with CGM use was supported in the selected articles (Barnard
et al., 2018; Edelman, 2017; Gilbert et al., 2021; Martin et al., 2019; Mattishent and Loke, 2018;
Schlüter et al., 2020). In addition, the article that gave insight into CGM use and cost was also
selected (Gill et al., 2018). Other articles whose studies were not yet complete were added
because they included foundational information on the importance of CGM use for all diabetes
patients challenged with unsuccessful glycemic control (Kieu et al., 2021; Lind et al., 2021).
Non-journal information obtained from the United States CDC, American Association of
Clinical Endocrinology (AACN), and NIDDK, was used to provide relevant statistical data used
to define the importance of glycemic control in diabetes patients.
The data rendered for this IR included eight systematic reviews, six randomized
controlled trials (RCTs), seven controlled cohort studies, two uncontrolled cohort studies, one
qualitative study, and two expert opinions. The latter was included because one of the expert
opinions provided an overview of the international consensus for the metrics TIR, which
strengthens CGM data reliability (Gabby et al., 2020). The other journal referenced increased
patient satisfaction with CGM use (Edelman, 2017). Overall, the articles selected for this IR
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addressed the clinical question using comprehensive methodologies or provided valuable insight
into CGM use’s practicality.
Conceptual Framework
The conceptual framework used for this IR is a version of Whittemore and Knafl’s
constant comparison method (2005). This process required and involved a methodical rigor
evaluation of primary literature data in evaluating each article’s relativeness to the research
question and each other. Each article obtained for this IR was evaluated, analyzed (reduced,
displayed, compared, and categorized), and conclusions were drawn based on recurring themes
in the findings (Toronto & Remington, 2020). The scientific underpinning framework for this IR
was based on the premise that a relationship between diabetes and HbA1c levels exists.
Understanding how this relationship is affected by glycemic management tools like CGMs can
help improve patient outcomes by improving the blood glucose level control. The research was
initiated using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) reporting guidelines (Moher et al., 2009) and Melnyk and Fineout-Overholt’s (2015)
pyramid levels of hierarchy tool. The methodology of IRs provided by Whitmore and Knafl
(2005) provided the framework umbrella for this IR. Using the constant comparative method,
each piece of data was compared and contrasted using the clinical question Does home-based
CGMs use by diabetes patients decrease HbA1c as the umbrella and principal guide to categorize
each piece of data into an appropriate category based on the article’s findings. In this IR,
evidence was arranged in a logical building order reflective of the clinical question (Whittemore
and Knafl, 2005) and formulated results. Appendix A shows a visual display of the literary
matrix and reduction analysis using the hierarchy levels by Melnyk and Fineout-Overholt (2015)
and Appendix B for formulated categories and themes created based on the data. According to
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Whittemore and Knafl (2005), an IR should present its findings logically and methodically based
on the evidence presented.
SECTION TWO: COMPREHENSIVE AND SYSTEMATIC SEARCH
Search Organization Reporting Strategy
Sources for this IR were obtained using a thorough systematic search approach (Toronto
and Remington, 2020) of six databases (Cochran Database, MEDLINE, CINAHL, Plus,
PubMed, ProQuest, and government websites). As described in the inclusion and exclusion
section, data were collected, reviewed, analyzed, and sorted. Based on Melnyk and FineoutOverholt’s (2015) pyramid levels of hierarchy tool, data for this IR was categorized first based
on its data type strength (Melnyk and Fineout-Overholt, 2015). The Melnyk and FineoutOverholt (2015) evidence tool qualifies literature sources based on defined hierarchy levels.
Level I is rated the highest and level VI the lowest in terms of rigor. Level I is assigned to
literature that includes a systematic review and meta-analysis of randomized controlled clinical
trials (p. 92), to which eight articles were assigned. Level II is assigned to literature that includes
one or more RCTs (p. 92), to which six articles were assigned. Level III is reserved for studies
that include controlled cohort and non-randomized studies (p. 92), to which seven articles were
assigned. Level IV includes studies that are uncontrolled cohort in nature (p. 92). Two of the 26
articles retained for this review project met this level of evidence. Hierarchy Level V is reserved
for literature that describes a review of descriptive and qualitative case studies or series,
evidenced-based project implementations, or quality improvement projects (p. 92). This review
identified one article that met this level of evidence. Level VI, the last and lowest level of the
Melnyk and Fineout-Overholt (2015) hierarchy of evidence, is reserved for an expert opinion
presented by someone who is believed to have a high level of knowledge regarding a topic. This
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IR contained two articles assigned to this level. This IR presents an analysis covering the
literature from the highest priority level (level I) of evidence to the lowest (level VI).
An IR requires a cohesive reporting method. The PRISMA tool is used to systematically
and in a categorical way, organize literature findings (Moher et al., 2009). The PRISMA tool was
adapted for this IR to provide a logistical visual flow of research data analyzed throughout this
IR to assist in the minimization of bias while increasing rigor of the review (Toronto and
Remington, 2020). The flow chart demonstrates the literary flow of topics: diabetes, CGM,
HbA1c, patient CGM use and costs, and the associated number of data that resulted from the
search.
Terminology
To minimize confusion in this IR, the word database when used refers to a searchable
electronic collection of published materials that include professional peer-reviewed journals and
publicly available government statistical data (Toronto and Remington, 2020). Furthermore, the
term search engine used in this IR describes an electronic library search of multiple databases
using the Jerry Falwell library located at Liberty University (Toronto and Remington, 2020).
SECTION III: METHODS: MANAGING THE COLLECTED DATA
The design method aligns with the activities associated with an evidenced-based IR
process that requires enhanced rigor and analysis (Whittemore and Knafl, 2005). The process
was initiated with a preliminary literature review, evaluation, appraisal, and synthesis of the best
available scientific evidence (Melnyk and Fineout-Overholt, 2015) relevant to adult patients with
diabetes, home-based CGM use, and HbA1c levels. Abstracts of the articles were read and
evaluated for topic relevancy, followed by a thorough evaluation for result relevancy. An
evidence-based literature synthesis matrix can be observed in Appendix A and was completed by
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one reviewer. The studies were evaluated for quality, bias, and clinical question relevancy using
the constant comparison method (Toronto and Remington, 2020). The PRISMA flowchart was
used to visually screen the article selection process (Moher et al., 2009) (see Appendix C and
Appendix E).

SECTION FOUR: QUALITY APPRAISAL
Sources of Bias
Any information that distorts study findings systematically that results from the study
methodology causes bias (Melnyk and Fineout-Overholt, 2015). Scholarly research requires
methods that ensure internal validity and that reduce bias (Toronto and Remington, 2020).
Reduction of bias in this IR article database was established using the PRISMA framework
(Moher et al., 2009) and Melnyk and Fineout-Overholt’s levels of hierarchy tool, which involved
the review, evaluation, analysis, and sorting of each article. (Melnyk and Fineout-Overholt,
2015). This analysis was completed to establish topic relevancy for use in this IR (Melnyk and
Fineout-Overholt, 2015). This effort yielded no findings of bias.
Internal Validity
When the study results are obtained using proper scientific methods, validity can be
established. Internal validity is important to establish because it relates the believability of
research results when the findings are obtained using appropriate scientific methods without bias
(Toronto and Remington, 2020). If internal validity is not established, external validity will not
be applicable. If external validity or generalizability cannot be established, the usefulness and
applicability of the findings in this IR to populations outside of this review are unlikely (Melnyk
and Fineout-Overholt, 2015).
Appraisal Tools (Literature Matrix)

HOME-BASED CONTINOUS GLUCOSED MONITORING

20

Critical appraisal of the evidence is highly recommended, but the appraisal tools and
methods used should align with the type of literature being reviewed (Toronto and Remington,
2020). With over 100 appraisal tools available for use, no gold standard appraisal tool has been
established to confirm quality ratings (Toronto and Remington, 2020). For this IR proposal,
empirical and theoretical data was evaluated first for topic relevancy and second for rigor of
methodology (Whittemore and Knafl, 2005). Diverse primary data collected was appraised for
relevance and quality using the Melnyk and Fineout-Overholt framework. The evidence was
placed into a matrix and categorized using the Melnyk and Fineout-Overholt’s levels of evidence
that ranks data from I to VI (Melnyk and Fineout-Overholt, 2015) as previously described.
Article themes was an additional categorical method used to categorize and synthesize articles
based on their theme trend (See Appendix B).
Applicability of Results
The 26 articles selected for this IR proposal were critically appraised and relevant to the
clinical topic of home-based CGM use and the lowering of HbA1c levels. The literary data was
organized and placed in the matrix by title, study purpose, sample size, methodology, results, and
limitations (Melnyk and Fineout-Overholt, 2015). Following a thorough review and
categorization of data based on themes observed in the literature reviewed, the data suggests that
CGMs used in the outpatient setting are useful self-monitoring tools that can aid in the reduction
of HbA1c levels for diabetes patients.
Reporting Guidelines
IRs are a data reporting method that allows for methodologies of diverse foundations that
offer varied perspectives of a phenomenon and are important to nursing science and practice
(Whittemore and Knafl, 2005). Each article in this IR was evaluated for the applicability of
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CGMs used in the out-patient setting and the lowering of HbA1c levels. To minimize bias and
increase transparency, PRISMA reporting and Melnyk and Fineout-Overholt’s (2015) appraisal
tools were used to arrange and report data (Toronto and Remington, 2020).
SECTION FIVE: DATA ANALYSIS AND SYNTHESIS
Data Analysis Methods
According to Whittemore and Knafl (2005), the analysis of data in the research of a
phenomenon requires that the primary data sources be “ordered, coded, categorized, and
summarized” and meshed into a unified conclusion (p. 550). The primary goal is to provide
additional insight to the IR clinical question, which is CGMs use and lowered HbA1c levels in
diabetes patients. Therefore, each article was placed in the Melnyk and Fineout-Overholt’s
(2015) level of evidence categorizing system, which allowed for repeated comparisons of
primary sources for topic relationship and then synthesized based on the themes observed during
the evaluation process. Moreover, study design, purpose, and data results were key evidence
information used to compare data for topic relevance and applicability.
Data Reduction
Determining a classification system that supports subgroups for the primary data is a
primary step for data reduction (Whittemore and Knafl, 2005). Logical placement of primary
data into subgroups aids in further data analysis (p. 550). For this IR, the evidence matrix used
was Melnyk and Fineout-Overholt (2015) literature classification system. Each article was
alphabetized by title and author and categorized into columns that divided and identified the
literature by study purpose, sample size, methods, study results, level of evidence (I-VI), study
limitations, and whether the study should be included in this IR study sample. Once categorized,
the articles were further coded, and information was extracted based on to what degree the
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clinical question was addressed or supported. This step increased the manageability of the
framework allowing for systematical comparison of the primary data (p. 550).
Data Display
The data display allows for further data extracted into subgroups or themes based on the
article concentration or focus related to the study question, according to Whittemore and Knafl
(2005). In this IR, there are two data display tables. First, one categorized all 26 articles
individually with categorical information, which separated the data (See Appendix A, the
Evidence Matrix Table). Second, data displayed has been presented in a table form with a
thematic display, where the articles were placed in categories based on the theme(s) presented,
which was derived using the constant comparison method (See Appendix B, the CGM Article
Matrix Table). Some articles were reflected in more than one theme. The thematic matrix allows
for data visualization related to the clinical question (p. 551).
Data Comparison
Whittemore and Knafl (2005) resolve the stance that sequential data analysis involves the
process of data comparison where the data display of the primary data requires the IR project
leader to order the data based on “identified patterns themes or relationships” (p. 551). The data
comparison phase sets the platform for the discernment of a conceptual map that shows the
relationship between the clinical question variables and themes presented in the data. In this IR,
the data comparison and visualization helped bring clarity which allowed for early interpretation
of the data (p. 551). In addition, this phase resulted in identifying meaningful higher-order
clusters of information that has been presented in the CGM article matrix table (See Appendix
B). The first and key relationship identified answered the clinical question concerning the
relationship between CGMs used in the out-patient setting by diabetes patients and the lowering
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of HbA1c levels. The second theme identified was the verification and reliability of the data
produced using CGMs, confirmed by demonstrating the inverse linear relationship between TIR
and HbA1c levels and hypoglycemia. This theme supports the first higher theme. The third
theme that surfaced was the diabetes patient’s acceptance and satisfaction with CGMs used in the
out-patient setting. The fourth theme represented was the value in reducing overall healthcare
costs associated with CGMs, and the last theme identified was the importance of CGM use with
dedicated plans for future studies.
Conclusion Drawing and Verification
According to Whittemore and Knafl (2005), this phase allows for IR in its entirety to be
displayed with a presentation of the subsets generalized in a format that allows for checks and
balances of the clinical question, variables, themes, and subsets to be reverified using the
primary sources for accuracy and final confirmation. This process was used and increased
correctness in drawing accurate IR conclusions that reflect the primary data. It must also be
noted that some themes were represented in more than one data set. This aids theme strength.
Article Themes Discussion
CGM use and HbA1c Reduction
Of the 26 articles evaluated, CGM use and reduction on HbA1c levels were found in 13
articles. Advani (2019) found that when TIR (a key GCM matrix) was greater than 70%, diabetes
patients experienced lowered HbA1c levels. Azhar et al. (2020), in their systemic review of 17
studies purposed to report CGM implications, found that two studies reported CGM use was
associated with lowered HbA1c levels and that T2DM users who commonly have less glycemic
variability than patients with T1DM had a higher significant reduction in their HbA1c levels than
in patients with T1DM. Beck et al. (2017), Eleftheriadou et al. (2019), and Gilbert et al. (2021),
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in their RCTs, reported reductions of HbA1c levels in patients with T2DM from 8.0% to 7.7%.
Eleftheriadou et al. (2019) found reductions from 8.0% to 7.6% and 7.6% to 7.1% in patients
with T1DM. When they evaluated patient responses to CGM use, Gilbert et al. (2021) found
reductions from 8.1% to 7.0% and 8.5% to 7.1% in patients with T1DM and T2DM, respectfully.
Chan et al. (2018) reported that CGM use was associated with lowered HbA1c levels in young
adults with cystic fibrosis. Al Hayek et al. (2017) found that when comparing SMBG and CGM
use, HbA1c levels were further reduced with the use of CGM device. Kropff et al. (2021) found
in their observational study to assess patient response to CGM use that HbA1c levels dropped
from 7.54% to 7.19%. Lameijer et al. (2021) evaluated data extracted from 16,331 analyzable
readers over 6-month and reported lowered eHbA1c levels. Martin et al. (2019), in their review
of six RCTs of advanced technologies of insulin pumps and CGMs, found that CGM use was
favored over the use of insulin pumps and HbA1c levels were reduced with CGM use when the
technologies were compared. Rivera-Ávila et al. (2021) evaluated the effects of CGM use in a
controlled study with 302 patients with T2DM whose HbA1c levels were above 8%. At the end
of 3 months, the intervention group experienced a mean difference of 0.439 lower HbA1c level
than the control group. Schlüter et al. (2020), in their evaluation of the SPECTRUM training
program for CGMs, found that patients experienced a reduction of HbA1c levels from 12%
down to 9%. Valenzano et at. (2021), in their study of 70 white patients with T1DM, first-time
CGMs users, found that in patients who experienced an increasingly higher percent of TIR, their
HbA1c levels lowered from 7.5% to 7.0%.
CGM Data Reliability: Linear Relationship Between TIR, HbA1c. and Hypoglycemia
Detection
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In a study to better understand the relationship between TIR, HbA1c, and hypoglycemia,
Beck et al. (2019), in a review of four RCTs involving 545 adult patients with T1DM, found that
TIR of 70% and 50% correlated to HbA1c levels of 7% and 8%, respectively. Hypoglycemia and
hyperglycemia are more accurately detected when TIR is > 70%. Fabris et al. (2020) desired to
bridge the gap between laboratory measured HbA1c levels. In 125 patients with T1DM, they set
out to determine the relationship between HbA1c levels and estimated HbA1c (eHbA1c) (CGM
obtained). They discovered that eHbA1c levels were 10% from reference HbA1c levels of 97.6%
and 96.3%. They concluded that HbA1c and TIR are reflections of the same underlying process
of glycemic fluctuation and that eA1c is an intermediate metric that can be used to assess
glycemic control with CGM use. These findings support the reliability of data provided using the
CGM devices. Gabby et al. (2020) conducted a technical review that provided insight and
overview of the international consensus in TIR. An expert opinion that recommends TIR use as a
new metric to evaluate glycemic control in diabetes patients. Al Hayek et al. (2017), in their
study described above, identified the inverse linear relationship between CGM use and HbA1c
levels and that CGM use was also associated with a reduction of hypoglycemic episodes, which
equated to less fear of hypoglycemia expressed by patients. Hirsch and Verderese (2017), in their
exploration of literature to assess the use of an ambulatory glucose profile reporting to
supplement current diabetic management tools, found that CGM use by diabetes patients helped
this population identify glycemic targets by identifying symptomatic hypoglycemia that could be
corrected. Kropff et al. (2017), also described above, found in their observational 180-days study
that 99.2 % of the participants experienced clinically acceptable error zones with hypoglycemic
events detected 81% of the time. Martin et al. (2019), in their review of six RCTs of patient
response to insulin pumps and CGM use, found that patients using CGMs experienced an
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increase in the detection of hypoglycemia. Mattishent et al. (2018), in their review of nine CGM
studies with 898 older diabetics, found that participants experienced a higher rate of detection of
asymptomatic hypoglycemic episodes. Ushigome et al. (2020), in their RCT study involving 18
patients with T2DM undergoing hemodialysis, aimed to evaluate if blood glucose control can be
evaluated using eHbA1c levels (obtained from the CGM device). The study helped determine
that eHbA1c obtained from CGM devices can be a reliable indicator for evaluating glycemic
control and avoiding hypoglycemia episodes in patients undergoing hemodialysis. Vigersky and
McMahon (2019), in their review of 18 articles and 1,137 participants over 10-years, found that
there were excellent correlations between HbA1c and % TIR in a linear relationship, which
confirms the reliability of CGM data. Xu et al. (2020), in their effort to evaluate the degree of
discrepancy of (eHbA1c) from CGM and laboratory HbA1c levels, found that the glycemic
marker eHbA1c accurately reflects laboratory HbA1c may provide a tool for assessing glycemia
over a variable time period using the CGM device. Finally, Yamada et al. (2020) also aimed to
evaluate the relationship between HbA1c and mean glucose levels in 59 patients with T1DM and
T2DM in the out-patient setting found a significant correlation between HbA1c and mean
glucose levels using the CGM. This relationship was stronger in patients with T2DM than in
patients with T1DM.
CGM Use, Patient Acceptance and Increased Patient Satisfaction
Barnard et al. (2018), in their systemic review on the implications of CGM involving 51
adult diabetes patients, found that new and old users prefer CGM use over traditional SMBG
tools. Both groups reported improved glycemic control with CGM use and favored continued
CGM use at the end of the study. Edelman (2017) provides an expert opinion regarding the
Dexcom 5 CGM where he reports patient acceptance and satisfaction of this newer CGM
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currently being marketed to all diabetes patients. In their study previously described, Gilbert et
al. (2021) also evaluated the psychosocial changes among patients with T1DM and T2DM
regarding CGM use. They found that patients were satisfied or very satisfied with CGM use.
Martin et al. (2019), with representation in the first two themes, also reported increased patient
satisfaction with CGM use. Mattishent et al. (2019), also represented in the theme above,
reported CGM use associated with patient acceptability and improved health-related wellness.
Schlüter et al. (2020), represented in previous themes, reported that in addition to the 3%
improvement in HbA1c levels, a secondary endpoint of their study included patient satisfaction
for CGM use, which was rated high.
CGM Use and Cost Reductions
Gill et al. (2018), in their retrospective cross-sectional analysis study of health care costs
and CGM, found in their review of 1,027 patients whose insurance pays for CGM use, spent on
approximately $4,200 less in total health care costs when compared with patients not using
CGMs. They also found that CGM user patients experienced fewer hospitalizations and better
glycemic control.
CGM Importance and Future Studies
Kieu et al. (2021) share plans of a future hierarchy level 1 study that provides a
systematic review protocol on the benefits of the addition of CGM use in the primary care setting
versus standard SMBG and HbA1c levels. Lind et al. (2021) have plans for a future RCT trial to
evaluate CGM use and patients with T2DM. The study was set to start from August 2020 to
August 2022 and aims to examine the effectiveness of CGM versus standard SMBG in patients
with insulin treated T2DM.
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Descriptive Results
This integrative review examined 26 articles from diverse data sources with variable
design styles enhancing a holistic understanding of CGM use, HbA1c levels, and their value to
diabetes patients (Whittemore and Knafl, 2005). The articles covered a recent time period of
2016–2021 with the interests of capturing studies that reflect the current state of the problem.
Themes and visual aids (see Appendices A–D) have been included to improve the logistics in the
presentation of this IR data. This IR has presented a literature analysis that answered the clinical
question surrounding the relationship between CGM use and lowered HbA1c levels. The data
presented support the phenomenon of an inverse linear relationship between CGM use among
diabetes patients and HbA1c levels. This relationship has been strengthened with the data
reliability demonstrated in CGM use and TIR. Hypoglycemia, a life-threatening situation, has
also been detected as a health benefit with CGM use. Some studies even indicated that CGM
linear relationship with HbA1c data in patients with T2DM was more strongly correlated than
results found in T1DM. This IR also provided insight into patients’ personal experiences and
increased satisfaction with CGM use. Gill et al. provided insight into the cost savings of
insurance covered CGM use. As CGM use increases, more studies ensue. This will add to the
body of knowledge of CGM use and benefits.
Synthesis
The 26 articles presented in this IR have provided information that answered the clinical
question (Toronto and Remington, 2020) of CGM use by adult diabetes patients and HbA1c
level reduction (Advani et al., 2019; Azhar et al., 2020; Beck et al., 2017; Chan et al., 2018;
Eleftheriadou et al., 2019; Gilbert et al., 2021; Al Hayek et al., 2017; Kropff et al., 2017;
Lameijer et al., 2021; Martin et al., 2019; Rivera-Ávila et al., 2021; Schlüter et al., 2020;
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Valenzano et al., 2021;) Other articles presented supported CGM data reliability by
demonstrating a linear relationship between TIR and HbA1c or eHbA1c and symptomatic and
asymptomatic hypoglycemia detection (Al Hayek et al., 2017; Beck et al., 2019; Fabris et al.,
2020; Gabby et al., Hirsch and Verderese, 2017; Kropff et al., 2017; Martin et al., 2019;
Mattishent and Loke, 2018; Ushigome et al., 2020; Vigersky and McMahon, 2019; Xu et al.,
2020; Yamada et al., 2020). Patient acceptance or satisfaction with CGM use was supported in
the selected articles (Barnard et al., 2018; Edelman, 2017; Gilbert et al., 202; Martin et al., 2019;
Mattishent and Loke, 2018; Schlüter et al., 2020). In addition, the article discussed that it gave
insight into CGM use and decreased health care cost was provided (Gill et al., 2018). Other
articles whose studies were not yet complete were discussed in the IR because they added
foundational information on the importance of CGM use for all diabetes patients challenged with
unsuccessful glycemic control (Kieu et al., 2021; Lind et al., 2021).
Ethical Considerations
This was an IR, and the IR project leader did not have direct contact with human
participants or exposure to identifiable participants’ data. Therefore, ethical concern was not
applicable to this study. Successful electronic submission and approval for this IR was received
by the Liberty University IRB and status of exemption was given (See Appendix C).
SECTION SIX: DISCUSSION
Implications for Practice/Future Work
Additional research is needed to further explain the hesitancy toward CGM use becoming
a covered insurance benefit by health plans. This IR has provided data to show that CGM use is
associated with many health benefits for diabetes patients and the U.S. healthcare economy. U.S.
Statistics have shown that current management tools such as SMBG have fallen short in helping
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diabetes patients improve glycemic control and prevent the development of cellular damage that
translates into increased co-morbidities, premature death and increased national expenditures,
and diabetes patients’ health care costs. When new knowledge of advanced technology
demonstrates improved patient outcomes and a reduction in overall health care costs for a group
of patients, healthcare policy changes should be considered. This IR has presented data that can
be used in the clinical guidelines for needed policy changes for diabetes patients, when using
CGM as an intervention management tool.
Dissemination
The intended audience for this IR is anyone interested in CGM use and its relationship to
HbA1c levels in diabetes patients in the community. It applies to clinicians who manage diabetes
patients and those who advocate for improved health care services and policy changes for this
population. Diverse methodologies were used in this IR to present the topic in a clear, systematic
way that answered the clinical question. With rising healthcare costs and an aging population,
improved ways to manage and improve glycemic control in diabetes patients should be a national
priority. This IR has presented data that demonstrated an alternative to standard SMBG and that
CGM use is associated with lowered HbA1c levels, CGM data have been deemed reliable, CGM
use is approved by the patients, and associated with health care cost savings. Dissemination of
information in this IR can be presented in a publication, poster format, or presented in its current
format.
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Table 1
Inclusion and Exclusion Criteria
Inclusion
Publication from 2016–2021
Adult diabetes patients > 18 y
Publications written in the English
language

Exclusion
Publication prior to 2016
Pediatric population < 18 y
Pregnant women
Publications written in a foreign language

Peer-reviewed journals

Non-peer-reviewed articles

Full-text articles

Abstract only articles

Out-patient setting

Hospital setting
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Appendix A
Evidence Matrix Table

Article Title,
Author

Study Purpose

Sample

Methods

Study Results

TIR is a key
metric for CGM
use in
determining
glucose control
and inversely
correlates with
HbA1c
*Patients
preferred the
CGM over the
finger-pricking
method.
*Increasing
scanning was
observed
*HbA1c levels
significantly
decreased.
Hypoglycemia
frequency
decreased.
*Patient fear of
hypoglycemia
decreased

Positioning
TIR in diabetes
management
(Advani, A.,
2019)

To summarize
guidance for
healthcare
professional in
helping patient
interpret TIR
goals

n = 64
resources

Systematic
Review

Evaluation of
FreeStyle
Libre Flash
glucose
monitoring
system on
glycemic
control, healthrelated quality
of life, and fear
of
hypoglycemia
in patients with
T1DM. (Al
Hayek et al.,
2017)

To evaluate
patient
experience with
the FreeStyle
Libre a CGM
device
compared with
traditional
finger-pricking
blood glucose
monitoring

n = 47 (aged
13–19) patients
at a diabetic
treatment center
in Riyadh,
Saudi Arabi.
64% of the
participants
were ages (1719)

A
prospective
study
conducted
between Jan
2021 and
May 2017

Level of
Evidence:
Melnyk
Framework

Study
Limitations

Level I

None discussed

Level III:
Controlled
cohort study

Small sample
size and the
inclusion of
only one center
for study

Would Use as
Evidence to
Support a
Change? (Yes or
No) Provide
Rationale
Yes: Provides
descriptive data
which helps with
clarifying TIR and
TBR

Yes. The study
adds to the body of
knowledge
regarding the
benefits of CGM
and lowering of
HbA1c levels
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A systematic
review on
clinical
implication of
CGM (Azhar,
Gillani,
Mohiuddin, &
Majeed, 2020)

To report
clinical
implications of
CGM use in
patients with
diabetes,
HbA1c,
estimated A1c,
and glucose
variability

n = 17 articles
from years
2017–2019

PRISMA
guidelines
were used to
study and
analyze data

When compared
with non-CGM
users, T1DM
and T2DM
CGM users had
a decrease in
HbA1c levels of
a significant
levels

Level I

Lack of
internationally
accepted
standards for
CGMs

Acceptability
of implantable
CGM
sensor. (Barnar
d et al. 2018)

Assess benefits
of CGM
including
psychosocial

51 T1DM (n =
46). T2DM (n
= 5) 18 yrs. +
patients across
the United
Kingdom and
Germany

A nonexperimental,
descriptive
survey.
PRECISE
trial.

Level V

Lack of
psychosocial
baseline data.
None listed by
researchers

The
relationships
between TIR,
hyperglycemia
metrics, and
HbA1c. (Beck
et al. 2019)

To understand
the relationship
between CGM
use, TIR (70–
180 mg/dL) of
metric and
patterns,
hyperglycemia,
and HbA1c
levels

545 adults with
T1DM (from
four random
trials) were
obtained from a
database with
centralized
laboratory
HbA1c results
and CGM
metrics

Analyses
from datasets
from four
RCT Crosssectional and
longitudinal
(6-months)

CGM devices
were favorable
to users, helped
to improve
glucose
management,
Both groups,
first-time users
and previous
users would like
to continue
CGM devices
TIR levels
averages
correlated in the
following way:
70% and 50%
corresponded
with HbA1c
levels
approximately
7% and 8%,
respectively. A
noted
considerable

Level I

Study data are
reflective of
individuals who
participated in
clinical trials,
which might
not be
representative
of the full
population of
adults with
T1DM

Yes: CGM use in
patients with
T2DM is still in its
infancy and this
systematic review
adds to the body of
knowledge
surrounding
support for validity
of results obtained
from CGMs
Yes. Descriptive
data is helpful.
Aids in
understanding
patient experiences
with CGMs use

Yes. Data adds
insight to CGMs
use and benefits. It
supports the
reliability of data
obtained from
CGMs and its
correlation to
HbA1c levels
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CGM versus
usual care in
patients with
T2DM
receiving
multiple daily
insulin
injections.
(Beck et al.
2017)

To evaluate the
effectiveness of
CGM use in
adults with
T2DM
receiving
multiple daily
injections of
insulin

HbA1c
accurately
predicts CGMderived
average
glucose in
youth and
young adults
with cystic
fibrosis. (Chan
et al. 2018)

To assess and
compare
glucose
markers:
HbA1c and an
average sensor
glucose (ASG)
in patients with
cystic fibrosis
with CGM use

25
endocrinology
practices in
North
American
158 participants
with T2DM,
randomly
assigned to
CGM: n = 79;
control group
(usual care) n =
79
39 patients with
cystic fibrosis
(CF) and 29
control group;
aged 6–25
years with
CGM use

RCT: 158
participants
with T2DM,
randomly
assigned to
CGM: n =
79; control
group (usual
care) n = 79

Controlled
cohort study
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spread of
change in
HbA1c for a
given change in
time-in-change
levels
Mean HbA1c
levels decreased
to 7.7% in the
CGM group and
8.0% in the
control group at
24 weeks

HbA1c levels
did not
underestimate
ASG as
previously
assumed. No
other glycemic
marker
correlated more
strongly with
ASG than
HbA1c levels

Level II

There was no 6- Yes. The data
month followoffers helpful
up
information to
describe the
beneficial
outcomes with
CGMs use and the
lowering of HbA1c
levels

Level III

Study estimates Yes
for average
glucose were
generated from
1 week of CGM
use, while
HbA1c
represents a
weighted
measure of
average glucose
over the
preceding 3 to 4
months.
Uncertainty of
comparisons of
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Regulation
catches up to
reality:
Nonadjunctive
use of CGM
data (Edelman,
S. 2017)

Commentary
regarding the
DEXCOM 5
and Food and
Drug
Administration
(FDA) approval

N/A

N/A

N/A

Level VI

diabetes
patients and CF
N/A

Improvement
of metabolic
control after
3-months
rtCGM use in
patients with
T1DM: A
multicenter
study in
Greece
(Eleftheriado
u et al., 2019)

To evaluate the
efficacy of
rtCGM added
to insulin pump
therapy for 3months

43 adult
patients with
T1DM on
insulin pump
therapy and
HbA1c > 7%

Data analysis
of
participants’
HbA1c at the
start of the
program and
3-months
post

At 3-months,
participants’
baseline HbA1c
levels decreased
from 8.0 to 7.6
and from 7.1 to
6.7 % (P <
0.001).
Nineteen
(44.2%) of the
sample had
HbA1c level
drop to < 7%

Level III

Not discussed

Yes. The study
validates CGM use
with the reduction
of HbA1c levels

Estimation of
HbA1c from
CGM data in
individuals
with T1DM: Is
TIR all we
need? (Fabris,
Heinemann,
Beck, Cobelli,
& Kovatchev,
2020)

To bridge the
gap between
laboratorymeasured
HbA1c and
CGM-derived
TIR,
introducing
TIR-driven
estimated A1c
(eA1c)

125 individuals
with T1DM,
and HbA1c at 3
months; and
168 individuals,
and HbA1c at
3, 6, and 9
months

Data from
Protocol 1
(training data
set) and
Protocol 3
(testing data
set) of the
International
Diabetes
ClosedLoop Trials
were used

Mean absolute
differences
between HbA1c
and eA1c 3- and
6-months post
calibration were
0.25% and
0.24%;
Pearson's
correlation
coefficients
were 0.93 and

Level II

Not discussed

Yes. The
information helps
to bridge the
knowledge gap of
HbA1c and TIR

Yes. Commentary
on patient
experience using
the DEXCOM 5
CGM device is
helpful

HOME-BASED CONTINOUS GLUCOSED MONITORING

42
0.93;
percentages of
eA1c within
10% from
reference
HbA1c were
97.6% and
96.3%,
respectively.
HbA1c and TIR
are reflections
of the same
underlying
process of
glycemic
fluctuation

TIR: A new
parameter to
evaluate blood
glucose control
in diabetes
patients
(Gabby et al.,
2020)
Change in
HbA1c and
quality of life
with rtCGM
use by people
with insulintreated
diabetes in
Landmark’s
study (Gilbert,

To provide an
overview of the
International
Consensus in
TIR

Diabetics using Technical
CGM
review
commentary

To evaluate
glycemia and
psychosocial
changes in
T1DM and
T2DM during
their first few
months of
CGM use

n = 248 (182
with T1DM and
66 with T2DM)

Real-world
prospective
study from
nationwide
callers who
placed orders
for the
Dexcom G6
CGMs.
Baseline and

Recommendatio
n of use of TIR
as a new and
useful metric to
evaluate
glycemic
control

Level VI:
Expert
Opinion

Limitations not
discussed

Yes: The
information shared
provides additional
insight that
supports CGM use
and data reliability

Mean HbA1c
levels for
patients with
T1DM
decreased from
8.1% to 7.0%
and for patients
with T2DM
HbA1c

Level IV

1. Lack of a
control group
and the absence
of baseline
blinded CGM
data.
2. Possible
heterogeneity in
HbA1c
measurement

Yes: Provides data
that CGM use is
associated with
lowered HbA1c
levels in patients
with T1DM and
T2DM
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12+ weeks
post HbA1c
levels were
compared

Noar, Blalock,
& Polonsky,
2021)

Health care
costs, hospital
admissions,
and glycemic
control using a
standalone,
rtCGM system
in
commercially
insured
patients with
T1DM. (Gill et
al., 2018)

To compare
health care
spending,
hospital
admissions, and
HbA1c levels
of patients
using rtCGM to
that of patients
not using
rtCGM

rtCGM
patients; n =
1,027
non-users,
n = 32,583

retrospective,
crosssectional
analysis that
used a large
repository of
health plan
administrativ
e data to
compare
average
health care
costs
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decreased from
8.5% to 7.1%.
93% of patients
were either
satisfied or very
satisfied with
the device. 73%
(70% of T1DM
and 80% of
T2DM) found it
very easy to use
Patients using
rtCGM spent an
average of
approximately
$4200 less in
total health care
costs when
compared with
patients not
using rtCGM
(P < .05). They
also
experienced
fewer hospital
admissions (P <
.05) and lower
HbA1c (P <
.05) during the
post-index year

method (pointof-care) vs.
laboratory
reporting

Level II

1. Optum
Yes. Links other
database does
health benefits to
not include
CGM use
actual allowed
amounts for
claims, which
caused the
researcher to
determine the
actual effect of
rtCGM on
spending. 2.
Optum database
includes only
direct costs;
thus, we were
unable to
evaluate the
impact of
rtCGM on
indirect costs,
such as days
missed from
work. 3. the
sample size for
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the subgroup of
patients for
whom HbA1c
data were
available was
relatively small

Professional
flash CGM
with
ambulatory
glucose profile
reporting to
supplement
HbA1c:
Rational and
practical
implementatio
n. (Hirsch &
Verderese,
2017)

To determine if
the use of a
standardized
report form
called the
ambulatory
glucose profile
(AGP)
supplemented
with CGM and
HbA1c levels is
a helpful
management
tool for
diabetes
patients

The exact
number of
medical
literatures,
professional
guidelines, and
real-world
evidence of
CGM use was
used to build an
integrative
practice
framework to
examine AGP
use was not
given

Benefits of the
addition of
continuous or
flash glucose
monitoring
versus standard
practice using
self-monitored

To compare
usual care use
of SMBG and
HbA1c and if
adding CGM in
primary care
patients
improves

This study was
planned from
February 2021
to December
2021

An
exploration
of literature,
professional
guidelines,
and
information
obtained
from CGM
users and
AGP use to
create
comprehensi
ve data that
reflects
practical
CGM use
and its
relationship
to HbA1c
levels
Systematic
Review of
RCT

CGM use helps Level 1
diabetes patients
to safely meet
glycemic targets
by identifying
symptomatic
hypoglycemia
that can be
corrected. AGP
use and HbA1c
monitoring can
aid clinicians
with translating
to patients the
long-term
benefits of
diligent
glycemic
control

No limitations
were discussed

Yes. The study
supports reliability
of CGM data and
linkage to HbA1c
levels

To be
determined

Not applicable

Yes. Preliminary
information
validates the
seriousness and
need for
improvements in
glucose

Level 1
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blood glucose
and HbA1c in
the primary
care of DM: a
systematic
review
protocol. (Kieu
et al., 2021)
Accuracy and
longevity of an
implantable
continuous
glucose sensor
in the
PRECISE
Study: A 180day,
prospective,
multicenter,
pivotal
trial. (Kropff et
al., 2017)
Flash glucose
monitoring in
the
Netherlands:
Increased
monitoring
frequency is
associated with
improvement
of glycemic
parameters.
(Lameijer et
al., 2021)

glycemic
control,
decrease rates
of
hypoglycemia,
and improve
patient and
physician
satisfaction?
To assess
patient
response to the
use of the
Eversense
implantable
CGM device,
device
accuracy, and
whether its use
increased
patient
glycemic
control
To evaluate the
association
between flash
glucose
monitoring
(FLASH)
frequency and
glycemic
parameters
during real-life
circumstances
in the
Netherlands
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management for
diabetes patients

Patients with
T1DM and
T2DM; n = 71,
aged 18 years
and older
multinational

An
observational
, 180-day
multicenter
pivotal trial

99.2% of
sample
clinically
acceptable error
zones with
hypoglycemic
events detected
81% of the time
within 30 mins.
Improved
HbA1c from
7.54 to 7.19.

Level III

No limitations
were shared by
researchers

Yes. Helpful
information
regarding
comparable CGM
devices

20 equally sized
rank ordered
groups (n =
817)

Data
extracted
from 16,331
analyzable
readers
between
September
2014 and
March 2020
were
analyzed

Increased scans
rates were
associated with
*a higher % of
TIR (3.9–10
mmol/L) (better
glycemic
control). *Less
time in
hyperglycemia
(> 10 mmol/L)
*Improvement
with eHbA1c

Level IV:
Uncontrolle
d cohort
study

1. Crosssectional study
design
precludes
conclusions
regarding
causality. 2.
Detailed
information
about the
FLASH users
was not
available.

Yes. The study
results support
improved glycemic
control with
FLASH CGM
system use
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rtCGM versus
selfmonitoring of
blood glucose
in adults with
insulin-treated
T2DM: a
protocol for a
center trial.
(Lind et al.,
2021)

This is a future
study aimed to
examine the
effectiveness of
CGM use
compared with
SMBG

Advanced
technology in
the

The review of
RCTs of
advanced

Recruitment of
adults with
T2DM for this
study started in
August 2020
and ended in
July 2021 with
a follow-up
planned for
August 2022.
The target aim
for participants
was 100

Planned for a
single-center,
prospective,
randomized,
open-labeled,
three-armed

Review of six
RCT

Summary of
reported
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To be
determined

Level II:
RCT

3.Lack of
information
regarding
carbohydrate
intake was not
available. 4.
Sub-groups not
identified. 5.
eHbA1c does
not always
closely
approximate
laboratory
measured
HbA1c
Researchers
discussed the
study’s possible
limitation with
generalizability
due to
exclusion
criteria.

The unblinded
methods of
the trial and
unforeseen
rates of
participant
dropout,
which could
bias the
results
CGM use
favored over
insulin pump.

Level 1
Systematic

Article did not
discussed
limitations

Yes. The study
introduction
highlights the
significance and
need for change
with addressing
glycemic control in
patients with
T2DM

Yes, the article
reports inverse
relationship
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management of
diabetes:
which comes
first – CGM or
insulin pump?
(Martin et al.,
2019)

technologies,
including the
CSII insulin
pump and
CGM for the
management of
diabetes in
patients with
T1DM

published
findings

Detection of
asymptomatic
drug-induced
hypoglycemia
using CGM in
older people –
a systematic
review
(Mattishent &
Loke 2018)

A systematic
review of CGM
use in older
patients and
hypoglycemia

9 studies with
898 older
diabetes
patients

The effects of
professional
CGM as an
adjuvant
educational
tool for
improving
glycemic

To evaluate the
effects of CGM
as an adjuvant
educational tool
for improving
glycemic
control in

n = 302
patients with
T2DM:
Intervention
group n = 150,
control group; n
= 152

Searched
Web of
Science,
Ovid SP
MEDLINE,
and
EMBASE
from January
2010 to June
2017 for
observational
studies and
RCT of
CGM in
older patients
(mean age 65
or older)
with diabetes
A 3-month
quasiexperimental
study with an
intervention
and control
group in one
family
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With CGM use
there was an
increased with
patient
satisfaction, an
increased in
hypoglycemia
detection and a
reduction of
HbA1c levels
Asymptomatic
Hypoglycemic
episodes codes
observed, CGM
acceptable and
experienced
improved
health-related
wellness

review of
RCTs

between CGM use
and HbA1c, and
increase patient
satisfaction

Level 1

Data included
Yes. Level 1
heterogenous
information,
which limits the
generalizability
to the general
older
population with
diabetes

At the end of the
3-month
follow-up, study
found a 0.439
mean HbA1c
difference
between the
groups (P =

Level III:
Nonrandomized
quasiexperimental
study with
the
intervention

1.This design is
“quasiexperimental”
because
assignment into
the intervention
and control
groups were not
random. 2.

Yes. Study supports
CGM use and
inverse relationship
to HbA1c
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control in
patients with
T2DM
(Rivera-Ávila
et al., 2021)

patients with
T2DM

medicine
clinic with
T2DM with
HbA1c levels
> 8% who
attended a
comprehensi
ve diabetes
program
involving
CGM use
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0.004), with an
additional
decrease in
HbA1c levels in
the intervention
group compared
with the control
group (Diff-inDiff HbA1c
mean of −
0.481% points, P
= 0.023).
*Compared with
the baseline, the
3-month CGM
patterns showed
a significant
increase in the
percentage of
time in glucose
range (+ 7.25; P
= 0.011); a
reduction in the
percentage of
time-above 180
mg/dL
(− 6.01; P =
0.045), a
decrease in
glycemic
variability (−
3.94, P = 0.034);
and
improvements in
dietary patterns,
shown
by a reduction in
total caloric

and control
group in one
family
medicine
clinic

Study did not
document
study
participants’
adherence to
pharmacological
and nonpharmacological
recommendation
s 3. Due to
logistical
restrictions, the
dietary and
glucose patterns
were only
measured in the
intervention
group.
4. The dietary
patterns were
assessed through
self-reporting,
which
potentially risks
over- or
under-estimating
the effect of the
intervention
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Evaluation of
the
SPECTRUM
training
program for
real-time
CGM: A realworld
multicenter
prospective
study in 120
adults with
T1DM.
(Schlüter et al.,
2020)

To evaluate
acceptance and
efficacy of a
training
program using
CGM among
patients with
T1DM 6months post
training

n = 120 T1DM
adult German
patients from
19 different
diabetes clinics
across
Germany. Full
study
completion n =
108

Evaluation of
seven core
competencies
and patient
satisfaction
using
questionnaire
using
(Students t
test, MannWhitney U
test,
ANOVA,
and KruskalWallis test).
Wilcoxon
signed-rank
tests were
used for
longitudinal
analysis

Critical
discrepancy in
blood glucose
control levels
evaluated by
GA and
estimated
HbA1c levels
determined
from a flash
CGM system

To investigate
if eHbA1c
levels obtained
from a flash
CGM could be
used to indicate
glycemic
control status in
diabetes
patients

n = 18
patients with
T2DM
undergoing
hemodialysis

RCT
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intake (− 197.66
Kcal/day; P =
0.0001)
Primary
endpoint:
rtCGM
knowledge
increase by
43%. Secondary
endpoint:
Patient
satisfaction:
High for CGM
use. Also,
HbA1c levels
reduced from
12% to 9%

The study
helped to
determine
eHbA1c
obtained from a
CGM device
can be used as a
reliable
indicator for
evaluating
glycemic

Level III:
Controlled
cohort study

1. A missing
controlled
group. Reasons
justified. CGM
use without
training would
be unethically
justifiable due
to potential
therapeutic
risks. 2.
Efficacy
comparable
data on other
training
programs not
available

Level II

FGM (flash
glucose
monitoring)
might be
underestimate
when blood
glucose levels
are low. GA
levels were
measured
within 1 week

Yes. Although the
study purpose was
specific to
researcher study
question for this IR,
results in study
answers important
questions related to
IR question
regarding CGM
and HbA1c. The
study results also
aligned with IR
findings related to
trend themes, such
as patient usability,
satisfaction with
CGM use,
reliability of CGM
data, and early
detection of
asymptomatic
hypoglycemia
Yes
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in patients with
T2DM
undergoing
hemodialysis.
(Ushigome et
al., 2020)

undergoing
hemodialysis

TIR-HbA1c
relationship
with CGM to
T1DM: A realworld study.
(Valenzano et
al., 2021)

To assess and
compare CGM
of patients with
T1DM,
TIR, and
HbA1c levels

The
Relationship of
HbA1c to TIR
in patients with
diabetes.
(Vigersky &
McMahon,
2019)

To evaluate the
relationship
between CGM
use among
diabetes
patients and
HbA1c levels

A kinetic
model for
glucose levels

To evaluate the
degree of
discrepancy

70 adult
Caucasian
raced patients
with T1DM
ages 20–60
with no
previous use of
CGM usage at
one diabetic
care center in
Toronto
n = 18 articles
which includes
1,137
participants:
CGM-HbA1c
and 1,140
participants:
SMBG-HbA1c

12-month
observation.
Statical data
evaluation
using linear
regression
models and
multivariate
OLS

Evaluation of
18 articles
from over a
10-year
period using
linear
regression
analysis and
Pearson’s
correlation
coefficient

120 diabetes
patients

Collection of
qualified
clinical data

50
control and
avoiding
hypoglycemic
episodes in
diabetes patients
undergoing
hemodialysis
0.5% decrease
in HbA1c levels
from 7.5% to
7.0% with a
mean
improvement of
the predicted
TIR percentages

before or after
FGM, which
could be a
source of bias

Level III

Not discussed.

Yes. Offers help
insight to this
population

Excellent
correlations
between HbA1c
and %TIR. The
presence of a
linear
relationship
between CGM
use and HbA1c
levels

Level I:
Systematic
review of
the literature

Yes. This data
validates the
reliability of
metrics data
obtained CGM.
Helps to establish
data reliability.
Data that can be
used to clinically
manage patients

Glycemic
marker cHbA1c
accurately

Level II

1. Only four of
the 18 articles
included
patients with
T2DM. 2. The
mean was
based on the
mean from
multiple
studies. 3. Most
of the patients
were
categorized as
white or nonHispanic
Limitations not
discussed

Yes: Level II and
articles offer
helpful information
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and HbA1c
provides a
novel tool for
individualized
diabetes
management.
(Xu, Dunn, &
Ajjan, 2020)

between
estimated
HbA1c
(eHbA1c)
levels created
with the use of
CGM and
laboratory
HbA1c

Evaluation of
the relationship
between
HbA1c and
mean glucose
levels derived
from the
professional
continuous
FGM system.
(Yamada et al.,
2020)

To evaluate the
relationship
between
glycated
HbA1c and
mean glucose
levels derived
from the
professional
continuous
FGM system

n = 59: T1DM
n = 28 T2DM n
= 31
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obtained
from
previous
studies

reflects
laboratory
HbA1c and may
provide a tool
for assessing
glycemia over a
variable time
period

Out-patients
using CGM
device
FreeStyle
Libre Pro
between
December
2016 and
August 2017.
Data
evaluated
using mean
and standard
deviation

Statistically
significant
correlation
between HbA1c
and mean
glucose levels
using the CGM
device, (r =
0.7248, P <
0.0001). This
relationship was
stronger in
patients with
T2DM than in
T1DM

regarding the
estimated HbA1c
levels and
laboratory HbA1c
levels

Level II

1. CGM data
was collected
for only 14
days (10.7 +/3.7). 2. The
study had a
cross-sectional
design and was
conducted by
recruiting
patients within
a single center

Yes. The study
adds to the
reliability of data
obtained from
CGMs and
validates the
consistent
relationship
between CGM use
usable data
regarding HbA1c
level interpretation
when managing
patient care
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Appendix B
CGM Article Matrix Table
CGM use and
HbA1c Reduction
n = 13

Advani A. (2019)

Al Hayek, Robert,
& Al Dawish (2017)
Azhar, A., Gillani,
S., Mohiuddin, G.,
& Majeed, R. A.
(2020)
Beck RW,
Riddlesworth TD,
Ruedy K, Ahmann
A, Haller S, Kruger
D, Janet B, McGil,
JB, & Polonsky, W.
(2017)

CGM Data
Reliability: Linear
Relationship
Between TIR and
HbA1c and
Hypoglycemia
Detection
n = 12
Beck RW,
Bergenstal RM,
Cheng P, Kollman
C, Carlson AL,
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Appendix C
PRISMA 2020 Checklist Reference

PRISMA 2020 Checklist
Section and
Topic

Item
Checklist item
#

TITLE
Title

1 Identify the report as a systematic review.

ABSTRACT
Abstract

2 See the PRISMA 2020 for Abstracts checklist.

INTRODUCTION
Rationale

3 Describe the rationale for the review in the context of existing knowledge.

Objectives

4 Provide an explicit statement of the objective(s) or question(s) the review addresses.

METHODS
Eligibility criteria

5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.

Information
sources

6 Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the
date when each source was last searched or consulted.

Search strategy

7 Present the full search strategies for all databases, registers and websites, including any filters and limits used.

Selection process

8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record
and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.

Data collection
process

9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked
independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the
process.

Data items

10a List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each
study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.
10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any
assumptions made about any missing or unclear information.

Study risk of bias
assessment

11 Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each
study and whether they worked independently, and if applicable, details of automation tools used in the process.

Effect measures

12 Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.

Synthesis
methods

13a Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and
comparing against the planned groups for each synthesis (item #5)).
13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data
conversions.
13c Describe any methods used to tabulate or visually display results of individual studies and syntheses.
13d Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the
model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.
13e Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).
13f Describe any sensitivity analyses conducted to assess robustness of the synthesized results.

Reporting bias
assessment

14 Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).

Certainty
assessment

15 Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.

Location
where item
is reported
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Appendix D

Identificat
ion

PRISMA 2020 Flow Diagram Systematic Review

Records identified through
databases searching
diabetes management tools
(n = 56,133 )

Additional records identified
through other sources
(n = 0)

Records with home-based CGM added
(n = 111)

Screening

Records with home-based CGM and HbA1c
(n = 100)

Records with home-based CGM and cost
(n = 112)

Records with home-based CGM and T2DM
(n = 162)

Included

Eligibility

Records screened after duplicates removed
(n = 103)

Full-text articles assessed for eligibility
(n = 50)

Records excluded
(n = 53)

Full-text articles excluded with
reasons
(n = 24)

Studies included in this integrative review
(n = 26)

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement:
an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
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